PLSE Stock Forecast: Pulse Biosciences, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Pulse Biosciences, Inc. hold a median 12-month price target of $68 — +48.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 54 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Pulse Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PLSE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PLSE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +48.1% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | Canaccord Genuity | Maintains | Buy | $58 → $74 |
| 6 Nov 2026 | Needham | Maintains | Buy | $58 → $64 |
| 13 Oct 2026 | Oppenheimer | Maintains | Outperform | $35 → $60 |
| 6 Oct 2026 | Canaccord Genuity | Maintains | Buy | $43 → $58 |
| 23 Sept 2026 | BTIG | Initiates | Buy | $70 |
| 9 Sept 2026 | Freedom Capital Markets | Initiates | Buy | $73 |
| 17 Aug 2026 | Needham | Initiates | Buy | $58 |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | $32 → $43 |
| 4 June 2026 | Canaccord Genuity | Initiates | Buy | $32 |
| 7 July 2025 | Oppenheimer | Initiates | Outperform | — |
| 21 Sept 2022 | Maxim Group | Downgrade | Hold | — |
| 13 May 2022 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 1 Apr 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Apr 2022 | Stephens & Co. | Maintains | Overweight | — |
| 10 Feb 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Nov 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 July 2021 | Stephens & Co. | Initiates | Overweight | — |
| 11 Mar 2021 | Maxim Group | Initiates | Buy | — |
| 26 Jan 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 May 2020 | H.C. Wainwright | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PLSE.
This page is one stock. Monday covers all of them.
PLSE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PLSE vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Pulse Biosciences, Inc. returned +260.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PLSE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 2259.6×
- Price / book
- 18.3×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 4% of US stocks
- Revenue growth (YoY)
- 359.3%
- Earnings growth (YoY)
- —
- Gross margin
- 37.1%
- Operating margin
- —
- Net margin
- —
Higher than 97% of US stocks
Higher than 45% of US stocks
- Return on equity
- −60.6%
- Return on assets
- −35.3%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pulse Biosciences, Inc. has a market value of $3.3B and an enterprise value of $3.1B.
Revenue in the twelve months to 30 June 2026: $1.2M.
Net income over the same four quarters: −$80.1M, a −6755.8% net margin.
Diluted earnings per share, trailing twelve months: −$1.18.
Free cash flow in the twelve months to 30 June 2026: −$61.4M.
Pulse Biosciences, Inc. employs 116 people — $10K of revenue per employee.
Data provided by Twelve Data
PLSE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PLSE’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Pulse Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PLSE
What is the PLSE stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Pulse Biosciences, Inc. have a median 12-month price target of $68, with estimates ranging from $60 to $74. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PLSE stock a buy right now?
Of the 6 analysts covering Pulse Biosciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulse Biosciences, Inc. 54 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PLSE?
As at 21 Nov 2026, Pulse Biosciences, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
Will PLSE stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +48.1% from the last close, and Ticker Nerd's factor model ranks Pulse Biosciences, Inc. 54 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PLSE stock forecast for 2030?
No analyst covering Pulse Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLSE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $74 over the next 12 months.
How has PLSE stock performed over the past year?
Pulse Biosciences, Inc. returned +260.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Pulse Biosciences, Inc. do?
Pulse Biosciences Inc is a bioelectric medicine company focused on developing and commercializing medical technologies that use proprietary pulsed-field energy to treat targeted cells while preserving surrounding tissue. Its current product portfolio includes the nPulse System for benign skin lesions, the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation, the nPulse Cardiac Surgical Clamp for atrial fibrillation procedures, the nPulse Cardiac Catheter System for circumferential cardiac ablation, and the nPulse Console, a software-enabled platform designed to support physician workflows.
About Pulse Biosciences, Inc.
Pulse Biosciences Inc is a bioelectric medicine company focused on developing and commercializing medical technologies that use proprietary pulsed-field energy to treat targeted cells while preserving surrounding tissue. Its current product portfolio includes the nPulse System for benign skin lesions, the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation, the nPulse Cardiac Surgical Clamp for atrial fibrillation procedures, the nPulse Cardiac Catheter System for circumferential cardiac ablation, and the nPulse Console, a software-enabled platform designed to support physician workflows. The company serves healthcare providers across dermatology, surgical soft-tissue care, and cardiac electrophysiology, with applications centered on minimally invasive treatment approaches. Pulse Biosciences Inc positions itself within the medical device market through its proprietary energy-based platform, which is designed for clinical use in areas where precise cellular targeting is important.
CEO Mr. Paul Arthur LaViolette M.B.A. · 116 employees · United States · https://www.pulsebiosciences.com